Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine

Guo,Zhongqiang; Zhang,Xiaoyu; Li,Xuesong; Xie,Feng; Su,Boxing; Zhang,Min; Zhou,Liqun

doi:10.3892/or.2014.3696

Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine

Authors:
- Zhongqiang Guo
- Xiaoyu Zhang
- Xuesong Li
- Feng Xie
- Boxing Su
- Min Zhang
- Liqun Zhou
View Affiliations

Affiliations: Department of Urology, Peking University First Hospital and The Institute of Urology, Peking University, Beijing 100034, P.R. China
Published online on: December 23, 2014 https://doi.org/10.3892/or.2014.3696
Pages: 1519-1525

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is a leading cause of cancer-related death among men. Early diagnosis and treatment are successful against prostate cancer, yet the clinical treatment of advanced prostate cancer remains a challenge. Gemcitabine is used to treat a broad spectrum of solid tumors; however, the clinical response of prostate cancer patients to gemcitabine is limited. In the present study, we showed that HMGN5, a nucleosome binding protein that can unfold chromatin by binding to histone (H1), is overexpressed in prostate cancer cells and plays an oncogenic role in prostate cancer tumorigenesis and development by activating the MAPK signaling pathway. We also found that sensitivity of prostate cancer cells to gemcitabine was positively correlated with HMGN5 expression. Knockdown of HMGN5 expression reduced the sensitivity of PC-3 cells to gemcitabine, and ectopic HMGN5 expression in DU145 cells enhanced the sensitivity to gemcitabine. Gemcitabine decreased HMGN5 expression, consequently leading to inactivation of the MAPK signaling pathway and cleavage of the PARP protein. Finally, we showed that PC-3 cells acquire gemcitabine resistance by gradual loss of HMGN5 expression. The present study suggests that HMGN5 is a potential biomarker for treating prostate cancer, and patients with a high level HMGN5 will benefit from gemcitabine treatment.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Harris WP, Mostaghel EA, Nelson PS and Montgomery B: Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 6:76–85. 2009. View Article : Google Scholar : PubMed/NCBI
3	Watson PA, Chen YF, Balbas MD, et al: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA. 107:16759–16765. 2010. View Article : Google Scholar : PubMed/NCBI
4	Abbruzzese JL: Phase I studies with the novel nucleoside analog gemcitabine. Semin Oncol. 23(Suppl 10): S25–S31. 1996.
5	Muenchen HJ, Quigley MM, Pilat MJ, et al: The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer. Anticancer Res. 20:735–740. 2000.PubMed/NCBI
6	Cronauer MV, Klocker H, Talasz H, et al: Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate. 28:172–181. 1996. View Article : Google Scholar : PubMed/NCBI
7	Morant R, Bernhard J, Maibach R, et al: Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 11:183–188. 2000. View Article : Google Scholar : PubMed/NCBI
8	Rochman M, Malicet C and Bustin M: HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. Biochim Biophys Acta. 1799:86–92. 2010. View Article : Google Scholar : PubMed/NCBI
9	Rochman M, Postnikov Y, Correll S, et al: The interaction of NSBP1/HMGN5 with nucleosomes in euchromatin counteracts linker histone-mediated chromatin compaction and modulates transcription. Mol Cell. 35:642–656. 2009. View Article : Google Scholar : PubMed/NCBI
10	Rochman M, Taher L, Kurahashi T, et al: Effects of HMGN variants on the cellular transcription profile. Nucleic Acids Res. 39:4076–4087. 2011. View Article : Google Scholar : PubMed/NCBI
11	Hock R, Furusawa T, Ueda T and Bustin M: HMG chromosomal proteins in development and disease. Trends Cell Biol. 17:72–79. 2007. View Article : Google Scholar
12	Shirakawa H, Rochman M, Furusawa T, et al: The nucleosomal binding protein NSBP1 is highly expressed in the placenta and modulates the expression of differentiation markers in placental Rcho-1 cells. J Cell Biochem. 106:651–658. 2009. View Article : Google Scholar : PubMed/NCBI
13	Shirakawa H, Landsman D, Postnikov YV and Bustin M: NBP-45, a novel nucleosomal binding protein with a tissue-specific and developmentally regulated expression. J Biol Chem. 275:6368–6374. 2000. View Article : Google Scholar : PubMed/NCBI
14	Wang JW, Zhou LQ, Yang XZ, et al: Up-regulated expression of a prostate cancer-related gene, NSBP1, in prostate cancer cells. Basic Med Sci Clin. 24:393–397. 2004.
15	Wahafu W, He ZS, Zhang XY, et al: The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol. 32:931–939. 2011. View Article : Google Scholar : PubMed/NCBI
16	Ji SQ, Yao L, Zhang XY, Li XS and Zhou LQ: Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo. J Exp Clin Cancer Res. 31:222012. View Article : Google Scholar : PubMed/NCBI
17	Han HJ, Russo J, Kohwi Y and Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 452:187–193. 2008. View Article : Google Scholar : PubMed/NCBI
18	Green J, Ikram M, Vyas J, et al: Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer. 94:1446–1451. 2006. View Article : Google Scholar : PubMed/NCBI
19	Rizzolio F, Bione S, Sala C, et al: Chromosomal rearrangements in Xq and premature ovarian failure: mapping of 25 new cases and review of the literature. Hum Reprod. 21:1477–1483. 2006. View Article : Google Scholar : PubMed/NCBI
20	Jiang N, Zhou LQ and Zhang XY: Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can inhibit the in vitro and in vivo proliferation of prostate cancer cells. Asian J Androl. 12:709–717. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhang XY, Guo ZQ, Ji SQ, et al: Small interfering RNA targeting HMGN5 induces apoptosis via modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells. Asian J Androl. 14:487–492. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zhang CJ, Li XS, Wahafu W, et al: Effect of paclitaxel and gemcitabine on the expression of nucleosomal binding protein 1 in bladder cancer cell line T24. Chin J Urol. 31:536–540. 2010.
23	Jiang N, Zhou LQ, Yao K and Huang C: The experimental investigation of androgen independent prostate cancer cell line inhibited growth in vivo by recombinant lentivirus of small interfering RNA (siRNA) targeting NSBP1. Chin J Clinicians. 4:154–157. 2010.
24	Wang Y, Guo Z, Ge Q, Wang E, Zhang X and Jin G: Preparation and characterization of RGD tumour-homing-peptide-modified plasminogen K5. Biotechnol Appl Biochem. 57:17–24. 2010. View Article : Google Scholar : PubMed/NCBI
25	Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R and Royuela M: MAP kinases and prostate cancer. J Signal Transduct. 2012:1691702012. View Article : Google Scholar
26	Buch-Hansen TZ, Bentzen L, Hansen S, et al: Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. Cancer Chemother Pharmacol. 66:295–301. 2010. View Article : Google Scholar
27	Di Lorenzo G, Autorino R, Giuliano M, et al: Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology. 69:347–351. 2007. View Article : Google Scholar : PubMed/NCBI
28	Garcia JA, Hutson TE, Shepard D, Elson P and Dreicer R: Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial. Cancer. 117:752–757. 2011. View Article : Google Scholar